Latest Development Programs News

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

Red Mountain Mining is making significant strides in its US critical minerals portfolio, reporting strong antimony assay results and gearing up for extensive exploration programs. The company’s projects align closely with US and Australian government initiatives to secure domestic critical metal supplies.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Matsa Resources launches a major drilling campaign at Fortitude North targeting up to 1.85 million ounces of gold, supported by a $17.5 million loan facility from major shareholder Deutsche Balaton.

Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.

Paradigm Biopharmaceuticals has published a pivotal study in PLOS ONE showing sustained pain relief and joint repair in dogs treated with pentosan polysulfate sodium, reinforcing its potential for human osteoarthritis therapy.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

Brightstar Resources has reported impressive high-grade gold assay results from its 2025 drilling campaign at the Sandstone Hub, setting the stage for a significant Mineral Resource upgrade and Pre-Feasibility Study later this year.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.